Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA Business Segments — Revenue

Similar metrics at other companies

HWK
HWKNPharmaceutical — Revenue
$8.32M+15.1%
Bausch + Lomb logo
BLCOPharmaceuticals — Total revenues
$266M+19.8%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Product revenues, net
$2.99B+7.8%
Pfizer logo
PFEProduct — Revenue
$11.72B+3.7%
Pfizer logo
PFEBiopharma — Revenues:
$14.16B+5.4%
Eli Lilly logo
LLYNet product revenue — Revenue
$18.45B+59.1%

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.24B+128%
Enterprise value$4.06B+139%
P/E58×—
P/S5.6×+1.8×

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's business segments — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's business segments — revenue?
Kiniksa Pharmaceuticals International, plc (KNSA) reported business segments — revenue of $214.27M in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's business segments — revenue changed year-over-year?
Kiniksa Pharmaceuticals International, plc's business segments — revenue increased by 55.5% year-over-year, from $137.79M to $214.27M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's business segments — revenue?
Over 2 years (2023 to 2025), Kiniksa Pharmaceuticals International, plc's business segments — revenue has grown at a 58.3% compound annual growth rate (CAGR), from $270.26M to $677.56M.
What does business segments — revenue mean?
The total gross income generated from the sale of pharmaceutical products and services within the segment. It serves as the primary indicator of market adoption and commercial success for the company's therapeutic portfolio.